8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) specializing in addictions must synthesize neurobiological, behavioral, and pharmacological evidence to deliver Trauma-Informed Care (TIC), implementing integrated, non-retraumatizing psychotherapies and safe psychopharmacological regimens for individuals presenting with Post-Traumatic Stress Disorder (PTSD) and co-occurring substance use disorders.

---

1. Neurobiology of Trauma, Stress Systems & Addiction Vulnerability

Hypothalamic-Pituitary-Adrenal (HPA) Axis & CRF Dysregulation

Psychological trauma, particularly when experienced during early critical neurodevelopmental windows, induces lasting structural and functional neuroendocrine alterations:

• Corticotropin-Releasing Factor (CRF) Hyperactivity: Traumatic stress induces persistent hypersecretion of CRF from the paraventricular nucleus of the hypothalamus and extrahypothalamic limbic structures—specifically the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST). Elevated central CRF drives persistent autonomic arousal, anxiety, and excessive vigilance.
• HPA Allostatic Shift: Chronic severe stress results in glucocorticoid receptor down-regulation or desensitization, leading to blunted or dysregulated cortisol diurnal curves. The normal negative feedback loop of cortisol is compromised, trapping the individual in a state of allostatic overload.

Neurocircuitry of Co-Occurring Trauma & Addiction:

                    [Trauma / Adverse Childhood Experiences]
                                      │
                                      ▼
    ┌─────────────────────────────────┴─────────────────────────────────┐
    ▼                                                                   ▼
[Hyperactive Amygdala & BNST]                         [Hypoactive vmPFC & Anterior Cingulate]
• Persistent hypersecretion of CRF                    • Loss of top-down inhibitory control
• Severe hyperarousal, terror, nightmares             • Impaired fear extinction learning
• Exaggerated acoustic startle reflex                 • Deficient behavioral self-regulation
    │                                                                   │
    └─────────────────────────────────┬─────────────────────────────────┘
                                      │
                                      ▼
                  [Intense Internal Dysphoria & Agony]
             (Nightmares, Flashbacks, Emotional Numbness)
                                      │
                                      ▼
                ["Self-Medication Hypothesis" (Khantzian)]
            Substances recruited as external chemical modulators:
            • Alcohol / Sedatives ──> Blunt hyperarousal & induce sleep
            • Opioids ──────────────> Extinguish emotional pain & terror
            • Cannabis ─────────────> Suppress nightmares (REM blunting)
            • Stimulants ───────────> Overcome emotional numbness/anhedonia

Functional Neuroanatomy: The Tripartite Circuit

1. Hyperactive Amygdala: Mediates conditioned fear acquisition, threat detection, and emotional memory consolidation. In PTSD, the amygdala fires excessively and indiscriminately to non-threatening environmental cues, initiating spontaneous sympathetic nervous system cascades (tachycardia, hypertension, diaphoresis).
2. Hypoactive Ventromedial Prefrontal Cortex (vmPFC) & Anterior Cingulate Cortex (ACC): The vmPFC normally exerts inhibitory, "braking" control over amygdalar output and mediates fear extinction. In trauma survivors, hypoactivation of the vmPFC permits unchecked amygdalar firing, impairing the capacity to suppress traumatic fear responses.
3. Hippocampal Atrophy & Contextual Deficits: High, sustained levels of glucocorticoids and stress-induced excitotoxicity produce dendritic remodeling and volume reduction in the hippocampus. Because the hippocampus provides spatio-temporal contextual tagging of memories, hippocampal dysfunction prevents the brain from recognizing that trauma is in the past; traumatic memories are re-experienced as occurring in the immediate present (intrusive flashbacks).

The "Self-Medication Hypothesis" in Trauma

Formulated by Edward Khantzian, the self-medication hypothesis posits that substance use is not primarily a pursuit of euphoria, but rather a compelling, functional attempt to alleviate unbearable, disordered affective states:

• Alcohol and Sedative-Hypnotics: Recruited to enhance GABAergic inhibition and suppress hyperadrenergic surges, panic, and hyperarousal.
• Opioids: Possess potent anti-rage, anti-anxiety, and psychic-pain blunting effects, chemically buffering the profound emotional agony and attachment rupture of developmental trauma.
• Cannabis: High concentrations of cannabinoids blunt REM sleep, temporarily suppressing trauma-related nightmares and nocturnal terrors.
• Stimulants: Used to pierce through severe emotional numbing, depersonalization, and profound anhedonia.

Adverse Childhood Experiences (ACEs) Epidemiology

The landmark CDC-Kaiser Permanente Adverse Childhood Experiences (ACE) Study revealed a staggering, graded dose-response relationship between early childhood abuse, neglect, and household dysfunction and adult addiction:

• An individual with an ACE score of 4 or higher is 5 times more likely to suffer from alcohol use disorder, 4 times more likely to suffer from depression, and 10 times more likely to engage in illicit drug use or injection drug use compared to someone with an ACE score of 0.
• In clinical substance use treatment programs, between 60% and 85% of patients report significant histories of physical, sexual, or emotional trauma, with co-occurring PTSD diagnosed in 30% to 50% of patients.

---

2. SAMHSA's Six Principles of Trauma-Informed Care (TIC)

Trauma-Informed Care represents an overarching philosophical and operational paradigm shift across healthcare delivery systems, moving fundamentally from asking "What is wrong with you?" to asking "What happened to you?" and "How did you learn to survive?"

SAMHSA's Six Core Principles of Trauma-Informed Care (TIC):

1. Safety ──────────────────────── Physical, psychological, and emotional safety
                                    for patients and healthcare staff.
2. Trustworthiness & Transparency ─ Clear, transparent operations, predictable
                                    rules, and explicit clinical boundaries.
3. Peer Support ─────────────────── Utilizing peer specialists with lived experience
                                    to build mutual hope and recovery capital.
4. Collaboration & Mutuality ────── Leveling power differentials; shared
                                    decision-making between clinician and patient.
5. Empowerment, Voice & Choice ──── Cultivating patient autonomy, self-advocacy,
                                    and recognizing innate resilience.
6. Cultural, Historical & Gender ── Moving beyond cultural stereotypes, addressing
   Issues                           historical trauma, and providing gender-responsive care.

Operational Clinical Modifications to Avoid Re-Traumatization

Traditional addiction treatment environments often inadvertently recreate dynamics of powerlessness, control, and violation characteristic of trauma. The APRN must lead operational reforms:

1. Physical Examinations and Invasive Procedures

• Clinical Vulnerability: Physical examinations, pelvic exams, or being unclothed can trigger severe panic, dissociation, or flashbacks in survivors of physical and sexual abuse.
• TIC Safeguards:
  • Always explain every component of the physical examination before touching the patient.
  • Obtain explicit verbal consent prior to each step ("May I listen to your lungs now?").
  • Allow patients to remain fully clothed as much as clinically feasible.
  • Ensure a chaperone is present, and inform the patient that they have the right to pause or terminate the exam at any moment.

2. Toxicology Testing

• Clinical Vulnerability: Observed urine drug screening (UDS)—where staff visually observe urine passing from the urethra into a cup—is profoundly invasive, humiliating, and directly replicates sexual violation and victimization.
• TIC Safeguards:
  • Reserve direct observation exclusively for rare, legally mandated circumstances.
  • Utilize alternative, respectful collection protocols: unobserved collection in single-occupancy restrooms with colored toilet water, temperature monitoring (90°F–100°F within 4 minutes), or transition to oral fluid (saliva) testing.
  • Never utilize toxicology results punitively (e.g., discharge from treatment or denial of psychiatric care); treat positive screens as vital clinical data indicating a need for intensified support.

3. Room Searches and Belonging Inspections in Residential Settings

• Clinical Vulnerability: Unannounced room searches or ransacking belongings replicates childhood home invasions and arbitrary boundary violations.
• TIC Safeguards:
  • Conduct searches only when clinically necessary for community safety, and always in the presence of the patient.
  • Explain the purpose transparently and treat personal possessions with dignity and care.

---

3. Evidence-Based Integrated Psychotherapies for PTSD and SUD

Seeking Safety (Lisa Najavits)

Seeking Safety is the premier, empirically validated present-focused cognitive-behavioral model designed specifically for co-occurring PTSD and substance use disorders:

• Present-Focused, Non-Exposure Design: Unlike traditional trauma therapies that require detailed trauma narratives and exposure to traumatic memories, Seeking Safety does not involve trauma exposure. This critical feature ensures it is exceptionally safe in early sobriety, active substance use, and acute withdrawal, completely avoiding the risk of trauma-induced substance relapse.
• Core Goal: Attaining Safety: The overarching principle is helping the patient achieve safety across four domains: safety in thinking (substituting coping thoughts for self-blame), safety in emotions (emotional regulation), safety in behavior (cessation of substance use and self-harm), and safety in interpersonal relationships (leaving abusive environments).
• Structure: 25 flexible, structured modules that can be delivered in individual or group formats across inpatient, residential, or outpatient settings.

Seeking Safety Core Therapeutic Architecture:

[Principle 1: Integrated Focus] ─── Addresses PTSD and SUD simultaneously in every session
[Principle 2: Present Focus] ────── Concentrates on current coping skills; NO trauma exposure
[Principle 3: Four Domains] ─────── Cognitive, Behavioral, Interpersonal, and Case Management
[Principle 4: Clinical Safety] ──── Safe in early recovery, active use, and severe instability

Exposure-Based Therapies in Addictions: CPT, PE & EMDR

Historically, exposure-based trauma therapies were strictly withheld until patients achieved 6 to 12 months of complete abstinence, based on clinical fears that confronting traumatic memories would trigger severe cravings and fatal overdose. Modern clinical trials (e.g., the Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure [COPE] trials) have overturned this dogma:

• Prolonged Exposure (PE): Involves in vivo exposure to avoided, safe trauma-related cues and imaginal exposure (repeated recounting of the trauma memory). When combined concurrently with Medication for Opioid Use Disorder (MOUD) or Medication for Alcohol Use Disorder (MAUD), PE can be initiated once baseline medical stability and emotional regulation skills are established. It produces superior reductions in PTSD symptom severity without increasing substance relapse.
• Cognitive Processing Therapy (CPT): A 12-session structured manualized therapy focusing on identifying and modifying "stuck points" (distorted core beliefs regarding safety, trust, power/control, esteem, and intimacy resulting from trauma). Highly effective when integrated into outpatient addiction recovery.
• Eye Movement Desensitization and Reprocessing (EMDR): Utilizes bilateral sensory stimulation (saccadic eye movements, alternating tactile taps, or auditory tones) while focusing on traumatic memories to facilitate adaptive neurobiological reprocessing. Adapted addiction protocols (e.g., Desensitization of Triggers and Urge Reprocessing [DeTUR]) specifically target substance memory networks and relapse triggers.

---

4. Pharmacotherapy for PTSD with Co-Occurring SUD

First-Line Antidepressant Pharmacotherapy

• FDA-Approved SSRIs: Sertraline (50 mg to 200 mg daily) and Paroxetine (20 mg to 50 mg daily) are the only two FDA-approved medications for PTSD.
  • Clinical Impact: Effective for reducing intrusive thoughts, hyperarousal, avoidance, and comorbid depressive symptoms.
  • Off-Label First-Line Options: Fluoxetine (20 mg to 60 mg daily) and Venlafaxine XR (75 mg to 225 mg daily) demonstrate comparable clinical efficacy in clinical trials.
  • Titration Mandate: Patients with PTSD and co-occurring panic frequently exhibit hypersensitivity to initial activating antidepressant side effects. The APRN should start at low doses (e.g., sertraline 25 mg daily) and titrate slowly over several weeks to achieve therapeutic doses.

Alpha-1 Adrenergic Antagonism: Prazosin for Trauma Nightmares

• Mechanism: Traumatic stress induces excessive nocturnal norepinephrine outflow from the locus coeruleus, disrupting REM sleep architecture, causing distressing autonomic arousals, violent motor activity, and terrifying trauma nightmares. Prazosin is a lipid-soluble alpha-1 adrenergic receptor antagonist that crosses the blood-brain barrier to competitively block central alpha-1 receptors, dampening nocturnal sympathetic surges.
• Clinical Indications: First-line off-label evidence-based pharmacotherapy for PTSD-related nightmares, nocturnal terrors, and fragmented sleep.
• Dosing & Titration Schedule:
  • Starting Dose: 1 mg PO at bedtime (to evaluate for first-dose syncope).
  • Titration: Increase by 1 mg to 2 mg every 3 to 7 days based on clinical response and tolerability.
  • Target Therapeutic Range: Typically 6 mg to 15 mg PO at bedtime for males; 2 mg to 8 mg PO at bedtime for females. (In severe daytime hyperarousal, small daytime doses of 1 mg to 2 mg PO may be added).
• Essential APRN Monitoring: Monitor resting blood pressure and pulse, specifically assessing for orthostatic hypotension, dizziness, lightheadedness, and syncope. Instruct patients to rise slowly from a seated or lying position.

The Strict Prohibition Against Benzodiazepines in PTSD & SUD

The American Psychological Association (APA), the Department of Veterans Affairs / Department of Defense (VA/DoD), and international clinical guidelines issue an unequivocal recommendation: Benzodiazepines are strictly contraindicated in the management of PTSD, and especially in co-occurring PTSD and substance use disorders.

Four Clinical Pillars Precluding Benzodiazepines in PTSD + SUD:

1. Impairment of Fear Extinction Learning:
   Benzodiazepines facilitate GABA-A transmission, blunting the neuroplasticity and
   amygdala-prefrontal synaptic remodeling required for fear extinction during trauma therapy.

2. Paradoxical Symptom Exacerbation:
   Longitudinal studies show patients on benzodiazepines exhibit worse long-term PTSD
   severity, higher rates of treatment-resistant depression, and increased emotional disinhibition.

3. High Addiction & Escalation Risk:
   PTSD patients rapidly develop tolerance, physical dependence, and escalating rebound anxiety
   between doses, driving compulsive misuse and illicit diversion.

4. Catastrophic Overdose Lethality:
   Co-ingestion of benzodiazepines with opioids (MOUD or illicit fentanyl) or alcohol
   causes synergistic brainstem respiratory arrest; present in >30% of fatal opioid overdoses.

---

5. Integrated Trauma-Addiction Clinical Decision Algorithm

Integrated Clinical Decision Algorithm for PTSD + SUD:

             [Patient Evaluated: Meets DSM-5-TR for PTSD + SUD]
                                    │
                                    ▼
                  [Establish Baseline Medical Safety]
                  • Initiate MOUD (Buprenorphine / Methadone) OR MAUD
                  • Overdose education & Naloxone distribution
                  • Implement Trauma-Informed Care environmental safeguards
                                    │
                                    ▼
       ┌────────────────────────────┴────────────────────────────┐
       ▼                                                         ▼
[Early Recovery / Active Use]                       [Stable Remission / Established MOUD]
(High instability, severe distress)                 (Good coping capacity, stabilized cravings)
       │                                                         │
       ▼                                                         ▼
[Seeking Safety (Najavits)]                         [Exposure-Based Trauma Psychotherapy]
• Present-focused coping skills                     • Prolonged Exposure (PE) OR
• Safe behavioral stabilization                     • Cognitive Processing Therapy (CPT) OR
• NO trauma narrative exposure                      • EMDR Protocol for Trauma/Addiction
       │                                                         │
       └────────────────────────────┬────────────────────────────┘
                                    │
                                    ▼
                   [Targeted Pharmacotherapy Suite]
                   • First-Line: Sertraline or Paroxetine (Slow titration)
                   • Trauma Nightmares: Prazosin (Titrate 1mg -> 6-15mg qHS)
                   • Breakthrough Agitation: Hydroxyzine PRN
                   • STRICT RULE: ZERO Benzodiazepines!

Pharmacotherapy Protocol Matrix for Co-Occurring PTSD and SUD